| 纯度 | >90%SDS-PAGE. |
| 种属 | Streptococcus |
| 靶点 | psaA |
| Uniprot No | P0A4G3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-309aa |
| 氨基酸序列 | CASGKKDTTSGQKLKVVATNSIIADITKNIAGDKIDLHSIVPIGQDPHEYEPLPEDVKKTSEADLIFYNGINLETGGNAWFTKLVENAKKTENKDYFAVSDGVDVIYLEGQNEKGKEDPHAWLNLENGIIFAKNIAKQLSAKDPNNKEFYEKNLKEYTDKLDKLDKESKDKFNKIPAEKKLIVTSEGAFKYFSKAYGVPSAYIWEINTEEEGTPEQIKTLVEKLRQTKVPSLFVESSVDDRPMKTVSQDTNIPIYAQIFTDSIAEQGKEGDSYYSMMKYNLDKIAEGLAK |
| 预测分子量 | 40.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于psaA重组蛋白的代表性文献摘要信息：
1. **标题**: "Immunization with recombinant Streptococcus pneumoniae adhesin A (rPsaA) protein elicits protective immunity in mice"
**作者**: Seo HS, et al.
**摘要**: 研究在大肠杆菌中成功表达并纯化psaA重组蛋白，证实其可诱导小鼠产生高效抗体，显著降低肺炎链球菌感染后的细菌载量，提示其作为疫苗候选的潜力。
2. **标题**: "Cloning and characterization of the psaA gene encoding the Streptococcus pneumoniae adhesin A"
**作者**: Sampson JS, et al.
**摘要**: 首次克隆psaA基因并在异源系统中表达重组蛋白，证明该蛋白在肺炎链球菌粘附宿主细胞过程中起关键作用，为后续致病机制研究奠定基础。
3. **标题**: "Structural and functional analysis of PsaA reveals a carbohydrate-binding module in pneumococcal adhesins"
**作者**: Lawrence MC, et al.
**摘要**: 通过X射线晶体学解析rPsaA的三维结构，发现其含特异性碳水化合物结合域，阐明了该蛋白介导细菌粘附的分子机制，为靶向抑制剂设计提供依据。
注：上述内容基于领域内典型研究方向模拟，实际文献需通过PubMed/Google Scholar检索确认。建议使用关键词"psaA recombinant protein vaccine"或"psaA structural analysis"查找最新研究。
**Background of psaA Recombinant Protein**
The *psaA* gene encodes the pneumococcal surface adhesin A (PsaA), a 37-kDa cell wall-anchored protein expressed by *Streptococcus pneumoniae*, a leading bacterial pathogen responsible for pneumonia, meningitis, and sepsis. PsaA plays a critical role in bacterial adherence to host epithelial cells, a key initial step in colonization and infection. Structurally, it functions as a manganese-binding lipoprotein, essential for manganese uptake—a process vital for bacterial survival, oxidative stress resistance, and virulence regulation.
Recombinant PsaA (rPsaA) is produced via genetic engineering, typically by cloning the *psaA* gene into expression systems like *Escherichia coli* or yeast, followed by purification. Its development stems from the need to study pneumococcal pathogenesis and host-pathogen interactions. As a conserved antigen across pneumococcal serotypes, rPsaA has garnered interest as a potential vaccine candidate. Unlike polysaccharide-based vaccines, which offer limited serotype coverage, protein-based vaccines targeting PsaA could provide broader protection by eliciting cross-reactive immune responses.
Preclinical studies demonstrate that rPsaA induces both humoral and cellular immunity, reducing bacterial colonization in animal models. Additionally, it is being explored in combination with other pneumococcal proteins (e.g., PspA, Ply) to enhance vaccine efficacy. Challenges remain in optimizing its immunogenicity and addressing structural complexity, but advancements in adjuvant systems and delivery platforms continue to drive progress. Beyond vaccinology, rPsaA serves as a tool for diagnostic assays and mechanistic studies on metal ion homeostasis in *S. pneumoniae*. Overall, rPsaA represents a promising target for next-generation interventions against pneumococcal diseases.
×
